Sulfinpyrazone

Sulfinpyrazone

Clinical data
Trade names	Apo-sulfinpyrazone
AHFS/Drugs.com	Monograph
MedlinePlus	a682339
Routes of administration	oral intravenous
ATC code	M04AB02 (WHO)
Pharmacokinetic data
Protein binding	98–99%
Metabolism	hepatic
Excretion	renal
Identifiers
IUPAC name 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione
CAS Number	57-96-5 Y
PubChem CID	5342
DrugBank	DB01138 Y
ChemSpider	5149 Y
UNII	V6OFU47K3W
KEGG	D00449 Y
ChEBI	CHEBI:9342 Y
ChEMBL	ChEMBL832 Y
CompTox Dashboard (EPA)	DTXSID0023618
ECHA InfoCard	100.000.325
Chemical and physical data
Formula	C23H20N2O3S
Molar mass	404.48 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C2N(c1ccccc1)N(C(=O)C2CCS(=O)c3ccccc3)c4ccccc4
InChI InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2 Y Key:MBGGBVCUIVRRBF-UHFFFAOYSA-N Y
(verify)

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.

Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.

Contraindications

Sulfinpyrazone must not be used in persons with renal impairment or a high rate of excretion of uric acid (hyperuricosuria).

Synthesis